126 related articles for article (PubMed ID: 35020667)
21. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor.
Rusthoven KE; Koshy M; Paulino AC
Cancer; 2004 Dec; 101(11):2641-9. PubMed ID: 15517576
[TBL] [Abstract][Full Text] [Related]
22. Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes?
Yen TC; Chang YC; Chan SC; Chang JT; Hsu CH; Lin KJ; Lin WJ; Fu YK; Ng SH
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):541-8. PubMed ID: 15625603
[TBL] [Abstract][Full Text] [Related]
23. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer.
Adams S; Baum RP; Stuckensen T; Bitter K; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1255-60. PubMed ID: 9724374
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET-CT in Unknown-Source of Elevated Serum Carcinoembryonic Antigen (CEA) Level.
Fu L; Li W; Tian X
J Coll Physicians Surg Pak; 2018 Dec; 28(12):910-913. PubMed ID: 30501825
[TBL] [Abstract][Full Text] [Related]
25. Role of FDG PET/CT for detection of primary tumor in patients with extracervical metastases from carcinoma of unknown primary.
Soni N; Ora M; Aher PY; Mishra P; Maheshwarappa RP; Priya S; Graham MM
Clin Imaging; 2021 Oct; 78():262-270. PubMed ID: 34174653
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
[TBL] [Abstract][Full Text] [Related]
27. FDG-PET/CT for detection of the unknown primary head and neck tumor.
Johansen J; Petersen H; Godballe C; Loft A; Grau C
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):500-8. PubMed ID: 22019707
[TBL] [Abstract][Full Text] [Related]
28. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of 18F-FDG positron emission tomography (PET) in the detection of unknown primary tumors].
Shinohara M; Tomita M; Ohira S; Nishimura A
Hokkaido Igaku Zasshi; 1999 May; 74(3):249-56. PubMed ID: 10422568
[TBL] [Abstract][Full Text] [Related]
30. Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
Zhang C; Liang Z; Liu W; Zeng X; Mo Y
BMC Cancer; 2023 Jan; 23(1):37. PubMed ID: 36624425
[TBL] [Abstract][Full Text] [Related]
31. The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up.
Yapar Z; Kibar M; Yapar AF; Paydas S; Reyhan M; Kara O; Buyukdereli G; Aydin M; Kelle AP; Unal I; Disel U; Yavuz S; Sahin B; Erkisi M
Nucl Med Commun; 2010 Jan; 31(1):59-66. PubMed ID: 19952921
[TBL] [Abstract][Full Text] [Related]
32. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis.
Ohira H; Tsujino I; Ishimaru S; Oyama N; Takei T; Tsukamoto E; Miura M; Sakaue S; Tamaki N; Nishimura M
Eur J Nucl Med Mol Imaging; 2008 May; 35(5):933-41. PubMed ID: 18084757
[TBL] [Abstract][Full Text] [Related]
33. FDG PET detection of unknown primary tumors.
Bohuslavizki KH; Klutmann S; Kröger S; Sonnemann U; Buchert R; Werner JA; Mester J; Clausen M
J Nucl Med; 2000 May; 41(5):816-22. PubMed ID: 10809197
[TBL] [Abstract][Full Text] [Related]
34. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
35. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation.
Jungehülsing M; Scheidhauer K; Damm M; Pietrzyk U; Eckel H; Schicha H; Stennert E
Otolaryngol Head Neck Surg; 2000 Sep; 123(3):294-301. PubMed ID: 10964310
[TBL] [Abstract][Full Text] [Related]
36. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
37. The impact of 18F-FDG PET/CT in the clinical management of patients with lymph node metastasis of unknown primary origin.
Nikolova PN; Hadzhiyska VH; Mladenov KB; Ilcheva MG; Veneva S; Grudeva VV; Dineva SE; Asenov YN
Neoplasma; 2021 Jan; 68(1):180-189. PubMed ID: 32880466
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT).
Lassen U; Daugaard G; Eigtved A; Damgaard K; Friberg L
Eur J Cancer; 1999 Jul; 35(7):1076-82. PubMed ID: 10533451
[TBL] [Abstract][Full Text] [Related]
39. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx.
Yen TC; Chang JT; Ng SH; Chang YC; Chan SC; Lin KJ; Lin WJ; Fu YK; Lin CY
J Nucl Med; 2005 Mar; 46(3):405-10. PubMed ID: 15750151
[TBL] [Abstract][Full Text] [Related]
40. Sensitivity of [18F]FDG PET/CT and classification of the primary tumor site in patients with carcinoma of unknown primary.
Atilgan HI; Yalcin H
Nucl Med Rev Cent East Eur; 2022; 25(1):1-5. PubMed ID: 35137930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
